EDIT - Editas Medicine, Inc.
After hours:
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 10.25 |
| Open | 10.38 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 10.00 - 10.69 |
| 52 Week Range | 6.33 - 19.97 |
| Volume | |
| Avg. Volume | 1,863,350 |
| Market Cap | 725.834M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.41 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.71 |
Fair Value
Related Research
GlobeNewswireEditas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on Monday, June 12, at 8:00 a.m. ET to present clinical data from the RUBY trial of EDIT-301 for the treatment of severe sickle cell disease. The Company will also present initial clinical data from the EDITHAL trial of EDIT-301 for the treatment of transfusion-dependent beta thalassemia. The webinar follows the oral p
InvestorPlace7 Short-Squeeze Stocks Set for a May Rally
A practice designed for only the most daring traders, the best short-squeeze stocks to buy now could yield tremendous gains. To be sure, approaching this sector means staring at the possibility of severe losses in the face. Still, because of the extreme risks involved, the rewards could be massive. To understand why, when bulls invest in a company, the risk is always that the security can go to zero. However, no upside price ceiling theoretically exists. Therefore, when bears take the opposite-s
- GlobeNewswire
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Erick Lucera. In connection with Mr. Lucera’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Mr. Lucera as an inducement material to Mr. Lucera entering into employment with Editas Medicine in accordance with Nasdaq Listing R
GlobeNewswireEditas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 Erick Lucera Editas Medicine today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023. CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023. Mr. Lucera wi
- GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Company-sponsored webinar to be announcedCAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in patients with severe sickle cell disease has been accepted for an oral presentation at the European Hematology Association (EHA) Hybrid Congress being held June 8-11, 2023, in Frankfurt, Germany, a
Simply Wall St.Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%
Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
ZacksEditas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.
Insider MonkeyEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript May 5, 2023 Operator: Good morning, and welcome to Editas Medicine’s First Quarter Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the […]
- Simply Wall St.
Editas Medicine First Quarter 2023 Earnings: Beats Expectations
Editas Medicine ( NASDAQ:EDIT ) First Quarter 2023 Results Key Financial Results Revenue: US$9.85m (up 46% from 1Q...
ZacksEditas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 10.13% and 97.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results and Business Updates
Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose 20 total patients by year-end in the RUBY trial First patient in EDIT-301 EDITHAL trial for TDT dosed with successful neutrophil and platelet engraftment; Company on track to provide clinical update by year-end Appointed Emma Reeve as Chair of the Board, effective at Annual Meeting of Stockholders, and
- GlobeNewswire
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the
- GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.Participants sh
InvestorPlaceThe 3 Most Promising Gene Editing Stocks to Buy in 2023
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it. That’s why CRISPR stocks that can edit genes have been in such demand both in research and in the biochemistry sector. But while gene editing can do many things, it can be hard to sort out science-fact from science-fiction. There are still many challenges that gen
ZacksCodexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the treatment of sickle cell disease. The FDA previously granted Orphan Drug Designation to EDIT-301 for the t
Insider Monkey12 Gene Editing Stocks With the Best Long-Term Potential
In this article, we will take a look at the 12 gene editing stocks with the best long-term potential. To see more such companies, go directly to 5 Gene Editing Stocks With the Best Long-Term Potential. Gene editing stocks are gaining ground on the back of an upbeat tone in the industry, helped by a […]
ZacksEarnings Preview: Editas Medicine (EDIT) Q1 Earnings Expected to Decline
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insider MonkeyTop 10 CRISPR Stocks To Buy
In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy. Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and […]
Motley FoolWhy Shares of Editas Medicine Rose Monday
Shares of clinical-stage biotech Editas Medicine (NASDAQ: EDIT) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also benefited from the news last week that the company was appointing a new chairman of the board and a new independent director. Several gene-editing companies saw their shares rise when it was reported that the Institute for Clinical and Economic Review (ICER), an independent group, said that exa-cel -- a one-dose treatment for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) being developed by CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) -- would be cost-effective, at under $1.9 million per dose, compared to the long-term costs most SCD patients face.
Motley Fool2 Stocks Under $15 Per Share to Consider
After all, if a company has excellent prospects, investors will flock to its shares, bidding them up. For two examples, consider Editas Medicine (NASDAQ: EDIT) and Snap (NYSE: SNAP). Editas Medicine is a biotech company that focuses on gene-editing therapies.
ZacksEditas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?
Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
GlobeNewswireEditas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
Elliott Levy, M.D. Editas Medicine announced the appointment of Elliott Levy, M.D., to its Board of Directors as an independent director. Emma Reeve Editas Medicine today announced the appointment of current Independent Director Emma Reeve as Chair of the Board. Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical st
Motley FoolProceed With Caution When Considering These 5 Ultra-Popular Stocks
AMC Entertainment (NYSE: AMC), SNDL (NASDAQ: SNDL), Netflix (NASDAQ: NFLX), Editas Medicine (NASDAQ: EDIT), and Tilray Brands (NASDAQ: TLRY) are some of the more popular stocks among retail investors. With the exception of Editas Medicine, all of them appear on the Top 100 most popular list among users of the Robinhood Markets trading platform.
Motley FoolBetter Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a question of which of these two biotechs has a higher chance of surviving over the next three years.